Trials / Completed
CompletedNCT03103256
Clinical Trial to Evaluate the Efficacy and Safety of YHP1701
A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine superiority of YHP1701 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YHP1701 | PO, Once daily (QD), 8 weeks |
| DRUG | YHR1703 | PO, Once daily (QD), 8 weeks |
| DRUG | YHR1704 | PO, Once daily (QD), 8 weeks |
Timeline
- Start date
- 2017-05-17
- Primary completion
- 2018-04-30
- Completion
- 2018-04-30
- First posted
- 2017-04-06
- Last updated
- 2018-09-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03103256. Inclusion in this directory is not an endorsement.